This printed article is located at https://investor.ouelh.com/news.html

News

Change - Announcement Of Cessation Of Chief Financial Officer

BackSep 10, 2021
Announcement Title Change - Announcement of Cessation
Date & Time of Broadcast Sep 10, 2021 22:00
Status New
Announcement Sub Title CESSATION OF CHIEF FINANCIAL OFFICER
Announcement Reference SG210910OTHR61XR
Submitted By (Co./ Ind. Name) Mr. Yet Kum Meng
Designation Chief Executive Officer and Executive Director
Description (Please provide a detailed description of the event in the box below) Cessation of Chief Financial Officer.

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.
Additional Details
Name Of Person Yik Yen Shan, Vincent
Age 48
Is effective date of cessation known? Yes
If yes, please provide the date 30/11/2021
Detailed Reason (s) for cessation Mr. Yik Yen Shan, Vincent ("Mr. Yik") had, on 9 September 2021, tendered his resignation as Chief Financial Officer of OUE Lippo Healthcare Limited (the "Company" and together with its subsidiaries, the "Group"), to pursue other career opportunities. Mr. Yik will be serving his notice period pursuant to his service contract with the Company and his last day of service with the Company will be 30 November 2021.

After having interviewed Mr. Yik and to the best of its knowledge, the Company's Sponsor, PrimePartners Corporate Finance Pte. Ltd., is satisfied that save as disclosed in this announcement, there are no other material reasons for the cessation of Mr. Yik as the Chief Financial Officer of the Company.

In addition, there are no concerns with regards to financial reporting that led to the cessation of Mr. Yik as the Chief Financial Officer and there are no disagreements between Mr. Yik and the Board of Directors (the "Board") of the Company with regards to practices that would have an impact to the Company's and/or the Group's financial reporting.

The Company is in the process of finding a suitable replacement for the position of Chief Financial Officer, and will make the necessary announcement when a suitable candidate is appointed.

The Board would like to extend its gratitude and appreciation to Mr. Yik for his invaluable contributions to the Company during his tenure of service.
Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting? No
Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer? No
Any other relevant information to be provided to shareholders of the listed issuer? No
Date of Appointment to current position 01/07/2019
Does the AC have a minimum of 3 members (taking into account this cessation)? Yes
Number of Independent Directors currently resident in Singapore (taking into account this cessation) 2
Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months 0
Job Title (e.g. Lead ID, AC Chairman, AC Member etc.) Chief Financial Officer
Role and responsibilities Responsible for the Group's overall financial and management accounting, treasury, taxation, investment management and other corporate matters.
Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries Nil.
Shareholding interest in the listed issuer and its subsidiaries? No
Past (for the last 5 years) Refer to Appendix A
Present Refer to Appendix B

Attachments

  1. Appendix A (Size: 82,357 bytes)
  2. Appendix B (Size: 130,284 bytes)
Please read our General Disclaimer & Warning carefully.
Use of this Website constitutes acceptance of the Terms of Website Use.
Copyright © 2022. ListedCompany.com. All Rights Reserved.